RHOVAC APS

RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. Overexpression of RhoC protein is a characteristic of most type of metastatic cancer cells. The cancer vaccine product RV001, already in clinical trial, recognises cells with high concentration of RhoC and stimulate the immune system to target them. RhoVac’s concept focuses on eliminating cancer cells having metastatic potential that escape treatment of the parent tumour via other methods. The company is based in Sweden and Denmark and is publicly traded in Swedish stock market. RhoVac is managed and advised by a senior team of executives with extensive expertise built upon years of experience.